Robert W. Duggan - Sep 10, 2025 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Role: Co-Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Robert W. Duggan
Stock symbol: SMMT
Transactions as of: Sep 10, 2025
Transactions value $: $5,984,756
Form type: 4
Date filed: 9/11/2025, 07:32 PM
Previous filing: Aug 19, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
DUGGAN ROBERT W	Co-Chief Executive Officer, Director, 10%+ Owner	C/O SUMMIT THERAPEUTICS INC., 601 BRICKELL KEY DRIVE SUITE 1000, MIAMI	/s/ Robert W. Duggan	2025-09-11	0001055919

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SMMT	Common Stock	Purchase	$5.89M	+333K	+0.06%	$17.68	556M	Sep 10, 2025	Direct	F1
transaction	SMMT	Common Stock	Purchase	$90.4K	+5K	+0%	$18.07	556M	Sep 11, 2025	Direct
holding	SMMT	Common Stock						31K	Sep 10, 2025	By Spouse	F2
holding	SMMT	Common Stock						10.2M	Sep 10, 2025	By the Shaun Zanganeh Irrevocable Trust, with the Spouse of Reporting Person as Trustee	F2
holding	SMMT	Common Stock						25.5M	Sep 10, 2025	By the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee	F2
holding	SMMT	Common Stock						50K	Sep 10, 2025	Immediate family member of Spouse	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.49 to $17.89 per share, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose

Content

The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.49 to $17.89 per share, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose